Pfizer: conclusive colorectal cancer treatment trial

(CercleFinance.com) - Pfizer announces that a Phase 3 trial has demonstrated that the combination of Braftovi (encorafenib), cetuximab (erbitux) and mFOLFOX6 significantly improved the objective response rate for the treatment of metastatic colorectal cancer with BRAF V600E mutation.


This combination showed a response rate of 60.9%, vs. 40.0% with chemotherapy.

The results, presented at the ASCO GI 2025 symposium and published in Nature Medicine, also indicate a potential benefit in overall survival.

This regimen received accelerated FDA approval in December 2024 and could become a standard for this patient population. In addition, the safety of this combination is in line with the known profiles of the agents used, the laboratory says.


Copyright (c) 2025 CercleFinance.com. All rights reserved.